NASDAQ: VTGN
Vistagen Therapeutics Inc Stock Ownership - Who owns Vistagen Therapeutics?

Insider buying vs selling

Have Vistagen Therapeutics Inc insiders been buying or selling?

Buy
Sell
NameRoleDateSharesPriceValue
Reid G. AdlerChief Legal Officer2025-06-307,541$1.70
$12.82kBuy
Cynthia Lynn AndersonCHIEF FINANCIAL OFFICER2025-06-306,617$1.70
$11.25kBuy
Joshua S. PrinceChief Operating Officer2025-06-304,882$1.70
$8.30kBuy
Shawn SinghPresident and CEO2025-06-307,541$1.70
$12.82kBuy
Cynthia Lynn AndersonCHIEF FINANCIAL OFFICER2024-12-312,592$2.51
$6.50kBuy
Joshua S. PrinceChief Operating Officer2024-12-313,310$2.51
$8.30kBuy

1 of 1

VTGN insiders have bought more... subscribe to Premium to read more.
Net Insider Buy/Sell (L12M) Ownership

Be the first to know when VTGN insiders and whales buy or sell their stock.

VTGN Shareholders

What type of owners hold Vistagen Therapeutics Inc stock?

Institutional
Insider
Retail
NameHoldSharesValueType
Venrock Healthcare Capital Partners II LP70.78%20,637,286$41.48MInsider
Holding Co Cato11.35%3,310,836$6.65MInsider
Tcg Crossover Management LLC9.18%2,676,580$5.38MInstitution
Stempoint Capital LP8.12%2,366,554$4.76MInstitution
Nantahala Capital Management LLC6.79%1,978,492$3.98MInstitution
Vanguard Group Inc6.72%1,960,172$3.94MInstitution
Commodore Capital LP5.40%1,575,000$3.17MInstitution
Platinum Long Term Growth VII LLC5.35%1,558,862$3.13MInsider
Commodore Capital LP2.74%799,244$1.61MInsider
Sphera Funds Management Ltd2.71%790,550$1.59MInstitution

1 of 3

VTGN vs Biotech Stocks

TickerInst. %Insider %Net Insider (L12M)Net Insider (L3M)
VTGN36.56%63.44%Net BuyingNet Buying
IRD4.48%95.52%Net Buying
VRCA31.87%53.14%Net Selling
CNTB5.09%0.00%
MGX25.46%33.19%Net SellingNet Selling

Vistagen Therapeutics Stock Ownership FAQ

Who owns Vistagen Therapeutics?

Vistagen Therapeutics (NASDAQ: VTGN) is owned by 54.68% institutional shareholders, 94.88% Vistagen Therapeutics insiders, and 0.00% retail investors. Venrock Healthcare Capital Partners II LP is the largest individual Vistagen Therapeutics shareholder, owning 20.64M shares representing 70.78% of the company. Venrock Healthcare Capital Partners II LP's Vistagen Therapeutics shares are currently valued at $42.10M.

If you're new to stock investing, here's how to buy Vistagen Therapeutics stock.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.